A Phase 2 interventional study of Volasertib and Cytarabine in Leukemia, Myeloid, Acute, sponsored by Boehringer Ingelheim. Completed at 27 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-03.
Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 247 studies testing cytarabine in Leukemia, Myeloid, Acute — 39 open to participants now, 45 under way, 10 of them phase 3. Cytarabine · Leukemia, Myeloid, Acute.
Among the 247 studies testing cytarabine in Leukemia, Myeloid, Acute, this one is the 35th largest by enrollment of the 239 interventional ones that give a count, is one of 9 that started in 2008, is one of 112 in phase 2, and was the 76th registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →39 of the 247 studies testing cytarabine in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:
Beijing 302 Hospital · Sites in China
Ages 18–70
The Methodist Hospital Research Institute · Sites in United States
Ages 18+
Sichuan Baili Pharmaceutical Co., Ltd. · Sites in China
Ages 18–75
Baylor College of Medicine · Sites in United States
Ages 1 mo–30 yrs
Fujian Medical University Union Hospital · Sites in China
Ages 14–60
By country, each count listing its studies:
Cytarabine: first FDA approval 1969 (CYTARABINE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
247 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 92 · Phase 2 156 · Phase 3 29 · Phase 4 3
First in 1993; this study’s year is marked. 9 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 180 is above the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 48 across the 239 interventional studies. Of the 168 that completed or were terminated, 79 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 247 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Boehringer Ingelheim has 9 studies filed under Leukemia, Myeloid, Acute — fewer than ten, so there is no comparison to draw.
9 of the studies testing cytarabine in Leukemia, Myeloid, Acute that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07514936Phase 3Chinese PLA General HospitalVenetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia | 2027-09-30 |
| NCT03330821University of Southern CaliforniaPevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia | 2026-12-31 |
| NCT06621212First Affiliated Hospital of Zhejiang UniversityMitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AML | 2026-12-31 |
| NCT04801797Massachusetts General HospitalVenetoclax + Azacitidine vs. Induction Chemotherapy in AML | 2027-01-01 |
| NCT06313437Richard Stone, MDRevumenib in Combination With 7+3 + Midostaurin in AML | 2027-03-02 |
Add all 9 to your calendar (.ics) → With an account.
Among the 247 studies testing cytarabine in Leukemia, Myeloid, Acute, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The trial will be performed in two parts, a phase I part and a phase IIa part. In the phase I part of the trial, BI 6727 will be investigated as monotherapy and in combination with low dose cytarabine (LD-Ara-C) in patients with relapsed/refractory AML that are not eligible for intensive treatment. The dose of BI 6727 will be escalated to determine the maximum tolerated dose (MTD) of BI 6727 monotherapy and BI 6727 in combination with LD-Ara-C in AML patients. In the phase IIa part, the combination of BI 6727 at MTD with LD-Ara-C and LD-Ara-C monotherapy will be investigated to explore the efficacy of the combination schedule in comparison to LD-Ara-C monotherapy in previously untreated AML patients that are not eligible for intensive treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male or female adult with AML ineligible for intensive treatment (phase I part only) Male or female adult with previously untreated AML ineligible for intensive treatment (phase IIa part only) Confirmed diagnosis of AML according to the WHO definition (except for acute promyelocytic leukaemia, APL) Patient is eligible for LD-Ara-C treatment > 3 months Eastern co-operative oncology group (, R01-0787) performance score \<=2 at screening Signed written consistent with international conference on harmonisation, good clinical practice (ICH-GCP) and local legislation
Exclusion criteria:
Previously untreated AML (phase I part only) or treatment refractory AML (phase IIa part only) Patient with APL (AML subtype M3 according to the French-American-British (FAB) classification) to one of the trial drugs or the Other requiring treatment Symptomatic central nervous system involvement (e.g. long QT syndrome, QTcF>470 ms) Aspartate amino transferase () or alanine amino transferase (ALT) greater than 2.5 times the (ULN), or AST or ALT greater than 5 times the ULN in case of known leukaemia liver involvement (PT) > 1.5 x ULN for subjects not on therapeutic vitamin K antagonists (phenprocoumon, warfarin) greater than 1.5 mg/dl (> 26 mcmol/L) Serum creatinine greater than 2.0 mg/dl Concomitant intercurrent illness, which would compromise the evaluation of efficacy or safety of the trial drug, e.g. active severe infection, unstable angina pectoris, cardiac arrhythmia or severe heart failure/cardiac insufficiency.
Psychiatric illness or social situation that would limit compliance with trial requirements Concomitant therapy, which is considered relevant for the evaluation of the efficacy or safety of the trial drug for cytarabine treatment according to the SPC Female patients of who are sexually active and unwilling to use a medically acceptable method of during the trial, i.e. combination of two forms of effective contraception (hormonal contraception, intrauterine device, condom with spermicide, etc.).
Male patients with partners of childbearing potential who are unwilling to use condoms in combination with a second medically acceptable method of contraception during the trial Pregnant or nursing female patients Patient unable to comply with the protocol
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Volasertib 150 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.
Drug: Volasertib · Drug: Cytarabine
Volasertib 200 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.
Drug: Volasertib · Drug: Cytarabine
Volasertib 250 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.
Drug: Volasertib · Drug: Cytarabine
Volasertib 300 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.
Drug: Volasertib · Drug: Cytarabine
Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.
Drug: Volasertib · Drug: Cytarabine
Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.
Drug: Volasertib · Drug: Cytarabine
Volasertib 150 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).
Drug: Volasertib
Volasertib 200 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).
Drug: Volasertib
Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).
Drug: Volasertib
Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).
Drug: Volasertib
Volasertib 450 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).
Drug: Volasertib
Volasertib 500 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).
Drug: Volasertib
Volasertib 550 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).
Drug: Volasertib
Low-dose cytarabine (LDAC) monotherapy 2x20 milligram (mg) per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.
Drug: Cytarabine
Volasertib 350 milligram (mg) on Days 1 and 15 (28-day cycle) administered by Intravenous Infusion (IV) over 60 minutes and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.
Drug: Volasertib · Drug: Cytarabine
Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).
Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.
Phase I: Maximum Tolerated Dose (MTD) of Volasertib in Combination With LDAC (Schedule A) and Volasertib Monotherapy (Schedule B)
To determine the Maximum tolerated dose (MTD), dose escalation was conducted following the 3+3 design with de-escalation. The MTD was defined as the highest dose at which 6 patients had been treated and less than 2 patients experienced a Dose limiting toxicity (DLT) within the first cycle of treatment. The MTD was defined based on safety data from the first cycle only. DLT is defined as drug related Common terminology criteria for adverse events (CTCAE) grade ≥ 3 nonhaematological toxicity (excluding: untreated nausea, untreated vomiting, CTCAE grade 3 untreated diarrhoea, CTCAE grade 3 "febrile neutropenia" and CTCAE grade 3 "infection with grade 3 or 4 neutrophils"). In patients with complete remission with incomplete blood count recovery (CRi) or partial remission (PR), persistent CTCAE grade 4 neutropenia or thrombocytopenia until three weeks after the end of the treatment cycle will be regarded a DLT.
Time frame: First Treatment cycle, up to 28 days.
Phase II: Number of Patients With Objective Response (Complete Remission (CR) + Complete Remission With Incomplete Blood Count Recovery (CRi))
Phase II: Number of patients with Objective Response (Complete remission (CR) + Complete remission with incomplete blood count recovery (CRi)). Complete remission (CR): morphologically leukaemia-free state (i.e. bone marrow with \<5% blasts by morphologic criteria and no Auer rods, no evidence of extramedullary leukaemia) and absolute neutrophil count ≥1,000/microliter (μL) and platelets \>100,000/μL. Complete remission with incomplete blood count recovery ("incomplete" CR, CRi): all of the above criteria for CR were met except that neutrophils \<1,000/μL or platelets \<100,000/μL in the blood were not achieved.
Time frame: The best overall response recorded during the time period from the start of the treatment until end of the treatment period, progression or death (whichever was earlier), up to 869 days.
Phase I: Number of Participants With Dose Limiting Toxicities (DLTs) in the First Cycle for the Determination of the Maximum Tolerated Dose (MTD)
A DLT was defined as a drug related CTCAE (Common Toxicity Criteria for Adverse Events) Grade ≥3 non-haematological toxicity (excluding untreated nausea, untreated vomiting, Grade 3 untreated diarrhea, Grade 3 febrile neutropenia, and Grade 3 infection with Grade 3 or 4 neutrophils). In patients with CRi (Complete Remission with Incomplete Blood Count Recovery) or PR (Partial Remission), persistent Grade 4 neutropenia or thrombocytopenia for 3 weeks after the end of the treatment cycle was regarded as a DLT unless the respective Grade 4 cytopenia was preexistent. In patients who required platelet substitution to maintain a Grade \<4 before treatment, a Grade 4 thrombocytopenia after treatment did not constitute a DLT.
Time frame: First Treatment cycle, up to 28 days.
Best Overall Response
* CR * CR+CRi * Partial remission: CR except bone marrow (BM) contained ≥5% but \<25% blasts (or ≤50% initial blasts), or \<5% blasts in presence of Auer rods or abnormal morphology. * No change: survived ≥7 days (d) after 1st cycle with persistent leukemia in last peripheral blood smear or BM, or with persistent extramedullary disease, without further deterioration due to leukemia or increase of blasts in BM or peripheral blood. * Aplasia: survived ≥7d after 1st cycle, died whilst cytopenic, with last post-treatment BM result aplastic or hypoplastic and without leukemia blasts. * Indeterminate: survived \<7 d after 1st cycle or survived ≥7d after 1st cycle, died with no persistent leukemia in peripheral smear but no post-treatment BM examination or did not complete 1st cycle. * Progressive disease: survived ≥7d after 1st cycle with increase of blast population in BM or peripheral blood or aggravation or new extramedullary disease or further deterioration or death due to leukemia.
Time frame: The best overall response recorded during the time period from the start of the treatment until end of the treatment period, progression or death (whichever was earlier), up to 869 days.
Phase I: Number of Patients With Objective Response: Complete Remission or Complete Remission With Incomplete Blood Count Recovery (CR+CRi)
Phase I: Number of patients with Objective Response (Complete remission (CR) + Complete remission with incomplete blood count recovery (CRi)). Complete remission (CR): morphologically leukaemia-free state (i.e. bone marrow with \<5% blasts by morphologic criteria and no Auer rods, no evidence of extramedullary leukaemia) and absolute neutrophil count ≥1,000/microliter (μL) and platelets \>100,000/μL. Complete remission with incomplete blood count recovery ("incomplete" CR, CRi): all of the above criteria for CR were met except that neutrophils \<1,000/μL or platelets \<100,000/μL in the blood were not achieved.
Time frame: The best overall response recorded during the time period from the start of the treatment until end of the treatment period, progression or death (whichever was earlier), up to 594 days.
Phase II: Event Free Survival
Event-free survival (EFS) \[days\] was the shortest duration of the following: (a) Date of assessment indicating PD on the response page of the eCRF (Electronic Case Report Form) - date of randomisation + 1 day (b) Date of assessment indicating clinical progressive disease (PD) on the disease or responses pages of the of eCRF- date of randomisation + 1 day (c) Date of assessment indicating PD on the patient status page of the eCRF - date of randomisation +1 day (for patients who had not been censored before this time point) (d) Death date - date of randomisation +1 day Patients not being assessed PD, clinical PD, or death during the trial were censored. EFS was analysed with the Kaplan-Meier method for each of the treatment arms.
Time frame: The patients that entered the trial, and measured from the date of randomization to the date of disease progression (treatment failure), relapse or death from any cause, whichever occurred first, up to 1000 days..
Phase II: Overall Survival
Overall survival \[days\] = (date of death - date of randomisation + 1 day), for patients with known date of death. Overall survival (censored) \[days\] = (date of last trial visit or follow-up - date of randomisation + 1 day), for patients who were still alive at time of database lock. Overall survival (OS) was analysed with the Kaplan-Meier method for each of the treatment arms.
Time frame: The patients that entered the trial, and measured from the date of randomisation until death from any cause, up to 1100 days..
Phase II: Relapse - Free Survival
Relapse-free survival \[days\] = (date of first recurrence of disease or death after entering the trial - date of first occurrence of CR or CRi after entering the trial+ 1 day) for patients with a recurrence (this value should be positive). Relapse-free survival (censored) \[days\] = (date of last trial visit or follow-up - date of first occurrence of CR or CRi after entering the trial + 1 day) for patients who did not experience recurrence of disease or death at the time of analysis.
Time frame: The patients who achieved CR or CRi, and was measured from the date of attaining CR or CRi until the date of disease recurrence or death from any cause, whichever occurred first, up to 900 days.
Phase II: Remission Duration
Remission duration analysis was defined only for patients who achieved Complete remission (CR) or Complete remission with incomplete blood count recovery (CRi), and was measured from the date of attaining CR or CRi until the date of disease recurrence (relapse). For patients who died without report of relapse, remission duration was censored on the date of death, regardless of cause.
Time frame: The patients who achieved CR or CRi, and was measured from the date of attaining CR or CRi until the date of disease recurrence (relapse), up to 900 days.
Phase II: Time to Remission
Time to remission \[days\] = (date of first occurrence of CR or CRi after entering the trial-date of randomisation + 1 day) for patients with an objective response.
Time frame: The patients who achieved CR or CRi, and was measured from the date of attaining CR or CRi until the date of disease recurrence (relapse), up to 158 days.
Best Eastern Co-operative Oncology Group (ECOG) Performance Score From Baseline Until End of Treatment
ECOG performance score change from baseline to last visit of last cycle = ECOG performance score at last visit of the last cycle - ECOG performance score at baseline. ECOG performance score changes from baseline were also categorised on a 3-point categorical scale: deteriorated (-1), unchanged (0), and improved (1). The number of participants for category of ECOG score change is reported.
Time frame: Baseline and End of Treatment (up to 869 days).
Total Clearance (CL) of Volasertib in Plasma After i.v (Intravenous) Administration of Volasertib
Total Clearance (CL) of Volasertib in Plasma after Intravenous (i.v.) Administration of Volasertib.
Time frame: Cycle 1: -0:05 hour (h), 0:30h, 1:00h, 1:30h, 2h, 3h, 4h, 24h, 96h, 216h, 335:55h, 336:30h, 337h, 337:30h, 338h, 339h, 340h, 648h after first drug administration.
Apparent Volume of Distribution of Volasertib at Steady State (VSS)
Apparent Volume of Distribution of volasertib at steady state (VSS) following Intravenous (i.v.) administration.
Time frame: Cycle 1: -0:05 hour (h), 0:30h, 1:00h, 1:30h, 2h, 3h, 4h, 24h, 96h, 216h, 335:55h, 336:30h, 337h, 337:30h, 338h, 339h, 340h, 648h after first drug administration.
Dose Normalized Maximum Measured Concentration of Cytarabine in Plasma (Cmax, Norm)
Cmax, norm: Maximum measured concentration of Cytarabine in plasma. The dose normalisation was done by dividing by the dose applied. Unit: nanogram/milliliter/milligram: ((ng/mL)/mg). Dose groups of Phase I were combined by dose normalizing as pre specified in the study protocol.
Time frame: Cycle 1: -0:05 hour (h), 0:30h, 1:00h, 1:30h, 2h, 3h, 4h, 24h, 96h, 216h, 335:55h, 336:30h, 337h, 337:30h, 338h, 339h, 340h, 648h after first drug administration.
Dose Normalized Area Under the Concentration-Time Curve of Cytarabine in Plasma Over the Time Interval From 0 Extrapolated up to 4 Hours
AUC0-4,norm: Area under the concentration-time curve of Cytarabine in plasma over the time interval from zero extrapolated to 4 hours. The dose normalisation was done by dividing by dose applied. Unit: nanogram\*hour/milliliter/milligram: ((ng\*h/mL)/mg). Dose groups of Phase I were combined by dose normalizing as pre specified in the study protocol.
Time frame: Cycle 1: -0:05 hour (h), 0:30h, 1:00h, 1:30h, 2h, 3h, 4h after first drug administration.
Absolute QTcF (QT Interval Corrected for Heart Rate Using Fridericia's Formula) Intervals
ECG (Electro Cardio Gram) Measurements: Absolute QTcF (QT Interval (interval from the beginning of the QRS complex to the end of the T wave) Corrected for Heart Rate Using Fridericia's Formula) Intervals. The 350 mg + LDAC arm of phase I and II were combined into one arm to provide maximum information on QT changes and presented together with the Phase I schedule B 450 mg arm, as pre specified in the study protocol.
Time frame: Baseline (Days -14 to -1) and day 1 (1 hour and 24 hours) after start of infusion.
QTcF (QT Interval Corrected for Heart Rate Using Fridericia's Formula) Change From Baseline at Cycle 1
ECG Measurements: QTcF (QT Interval (interval from the beginning of the QRS complex to the end of the T wave) changes from baseline at each time point: The QTcF post baseline measurement obtained at time t minus baseline QTcF measurement. The 350 mg + LDAC arm of phase I and II were combined into one arm to provide maximum information on QT changes and presented together with the Phase I schedule B 450 mg arm, as pre specified in the study protocol.
Time frame: Baseline (Days -14 to -1) and day 1 (1 hour and 24 hours) after start of infusion.
Phase I Schedule A: Number of Participants With Adverse Events (AEs) Graded According to Common Terminology Criteria for Adverse Events (CTCAE), Based on the Number of Patients With AEs With CTCAE Grade ≥3 During Cycle 1
Number of patients with AEs following in the categories 3 (severe AE), 4 (life-threatening or disabling AE), 5 (death related AE) of CTCAE is reported.
Time frame: First treatment cycle, up to 28 days.
Phase I Schedule B: Number of Participants With Adverse Events (AEs) Graded According to Common Terminology Criteria for Adverse Events (CTCAE), Based on the Number of Patients With AEs With CTCAE Grade ≥3 During Cycle 1
Number of patients with AEs following in the categories 3 (severe AE), 4 (life-threatening or disabling AE), 5 (death related AE) of CTCAE is reported.
Time frame: First treatment cycle, up to 28 days.
Phase I Schedule A: Number of Participants With Adverse Events (AEs) Graded According to Common Terminology Criteria for Adverse Events (CTCAE), Based on the Number of Patients With AEs With CTCAE Grade ≥3 During All Cycles
Number of patients with AEs following in the categories 3 (severe AE), 4 (life-threatening or disabling AE), 5 (death related AE) of CTCAE is reported.
Time frame: From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 615 days.
Phase I Schedule B: Number of Participants With Adverse Events (AEs) Graded According to Common Terminology Criteria for Adverse Events (CTCAE), Based on the Number of Patients With AEs With CTCAE Grade ≥3 During All Cycles
Number of patients with AEs following in the categories 3 (severe AE), 4 (life-threatening or disabling AE), 5 (death related AE) of CTCAE is reported.
Time frame: From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 597 days.
Phase II: Number of Participants With Adverse Events (AEs) Graded According to Common Terminology Criteria for Adverse Events (CTCAE), Based on the Number of Patients With AEs With CTCAE Grade ≥3 During All Cycles
Number of patients with AEs following in the in the categories 3 (severe AE), 4 (life-threatening or disabling AE), 5 (death related AE) of CTCAE is reported.
Time frame: From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 890 days.
Open-label, randomized, dose escalation study. In this trial 180 patients were entered and randomised. However 3 patients were entered but not treated in Phase I and 2 patients were not treated in Phase II. Thus total 175 patients were treated in this trial.
| Milestone | Phase I Schedule A. Volasertib 150 mg+LDAC | Phase I Schedule A. Volasertib 200 mg+LDAC | Phase I Schedule A. Volasertib 250 mg+LDAC | Phase I Schedule A. Volasertib 300 mg+LDAC | Phase I Schedule A. Volasertib 350 mg+LDAC | Phase I Schedule A. Volasertib 400 mg+LDAC | Phase I Schedule B. Volasertib 150 mg | Phase I Schedule B. Volasertib 200 mg | Phase I Schedule B. Volasertib 350 mg | Phase I Schedule B. Volasertib 400 mg | Phase I Schedule B. Volasertib 450 mg | Phase I Schedule B. Volasertib 500 mg | Phase I Schedule B. Volasertib 550 mg | Phase II Schedule C. LDAC | Phase II Schedule A. Volasertib 350 mg+LDAC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 4 | 3 | 5 | 9 | 8 | 3 | 11 | 2 | 5 | 6 | 23 | 5 | 4 | 45 | 42 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 4 | 3 | 5 | 9 | 8 | 3 | 11 | 2 | 5 | 6 | 23 | 5 | 4 | 45 | 42 |
| Withdrew: Progressive disease | 3 | 2 | 4 | 6 | 4 | 1 | 8 | 2 | 4 | 5 | 12 | 2 | 2 | 26 | 20 |
| Withdrew: Dose limiting toxicity (dlt) | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Other adverse event | 1 | 1 | 1 | 2 | 2 | 1 | 3 | 0 | 0 | 1 | 5 | 2 | 0 | 6 | 13 |
| Withdrew: Non compliance with protocol | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Refused to continue medication | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 1 | 1 | 5 |
| Withdrew: Other reason than listed above | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 3 | 1 | 1 | 10 | 3 |
To determine the Maximum tolerated dose (MTD), dose escalation was conducted following the 3+3 design with de-escalation. The MTD was defined as the highest dose at which 6 patients had been treated and less than 2 patients experienced a Dose limiting toxicity (DLT) within the first cycle of treatment. The MTD was defined based on safety data from the first cycle only. DLT is defined as drug related Common terminology criteria for adverse events (CTCAE) grade ≥ 3 nonhaematological toxicity (excluding: untreated nausea, untreated vomiting, CTCAE grade 3 untreated diarrhoea, CTCAE grade 3 "febrile neutropenia" and CTCAE grade 3 "infection with grade 3 or 4 neutrophils"). In patients with complete remission with incomplete blood count recovery (CRi) or partial remission (PR), persistent CTCAE grade 4 neutropenia or thrombocytopenia until three weeks after the end of the treatment cycle will be regarded a DLT.
| milligram (mg) | Phase I Schedule A. Volasertib+LDAC | Phase I Schedule B. Volasertib |
|---|---|---|
| Phase I: Maximum Tolerated Dose (MTD) of Volasertib in Combination With LDAC (Schedule A) and Volasertib Monotherapy (Schedule B) | 350 | 450 |
Phase II: Number of patients with Objective Response (Complete remission (CR) + Complete remission with incomplete blood count recovery (CRi)). Complete remission (CR): morphologically leukaemia-free state (i.e. bone marrow with \<5% blasts by morphologic criteria and no Auer rods, no evidence of extramedullary leukaemia) and absolute neutrophil count ≥1,000/microliter (μL) and platelets \>100,000/μL. Complete remission with incomplete blood count recovery ("incomplete" CR, CRi): all of the above criteria for CR were met except that neutrophils \<1,000/μL or platelets \<100,000/μL in the blood were not achieved.
| Participants | Phase II Schedule C. LDAC | Phase II Schedule A. Volasertib 350 mg+LDAC |
|---|---|---|
| Phase II: Number of Patients With Objective Response (Complete Remission (CR) + Complete Remission With Incomplete Blood Count Recovery (CRi)) | 6 | 13 |
A DLT was defined as a drug related CTCAE (Common Toxicity Criteria for Adverse Events) Grade ≥3 non-haematological toxicity (excluding untreated nausea, untreated vomiting, Grade 3 untreated diarrhea, Grade 3 febrile neutropenia, and Grade 3 infection with Grade 3 or 4 neutrophils). In patients with CRi (Complete Remission with Incomplete Blood Count Recovery) or PR (Partial Remission), persistent Grade 4 neutropenia or thrombocytopenia for 3 weeks after the end of the treatment cycle was regarded as a DLT unless the respective Grade 4 cytopenia was preexistent. In patients who required platelet substitution to maintain a Grade \<4 before treatment, a Grade 4 thrombocytopenia after treatment did not constitute a DLT.
| Participants | Phase I Schedule A. Volasertib 150 mg+LDAC | Phase I Schedule A. Volasertib 200 mg+LDAC | Phase I Schedule A. Volasertib 250 mg+LDAC | Phase I Schedule A. Volasertib 300 mg+LDAC | Phase I Schedule A. Volasertib 350 mg+LDAC | Phase I Schedule A. Volasertib 400 mg+LDAC | Total Phase I Combined. Schedule A. | Phase I Schedule B. Volasertib 150 mg | Phase I Schedule B. Volasertib 200 mg | Phase I Schedule B. Volasertib 350 mg | Phase I Schedule B. Volasertib 400 mg | Phase I Schedule B. Volasertib 450 mg | Phase I Schedule B. Volasertib 500 mg | Phase I Schedule B. Volasertib 550 mg | Total Phase I Combined. Schedule B. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phase I: Number of Participants With Dose Limiting Toxicities (DLTs) in the First Cycle for the Determination of the Maximum Tolerated Dose (MTD) | 0 | 0 | 0 | 1 | 1 | 2 | 4 | 1 | 0 | 0 | 1 | 1 | 2 | 2 | 7 |
* CR * CR+CRi * Partial remission: CR except bone marrow (BM) contained ≥5% but \<25% blasts (or ≤50% initial blasts), or \<5% blasts in presence of Auer rods or abnormal morphology. * No change: survived ≥7 days (d) after 1st cycle with persistent leukemia in last peripheral blood smear or BM, or with persistent extramedullary disease, without further deterioration due to leukemia or increase of blasts in BM or peripheral blood. * Aplasia: survived ≥7d after 1st cycle, died whilst cytopenic, with last post-treatment BM result aplastic or hypoplastic and without leukemia blasts. * Indeterminate: survived \<7 d after 1st cycle or survived ≥7d after 1st cycle, died with no persistent leukemia in peripheral smear but no post-treatment BM examination or did not complete 1st cycle. * Progressive disease: survived ≥7d after 1st cycle with increase of blast population in BM or peripheral blood or aggravation or new extramedullary disease or further deterioration or death due to leukemia.
| Participants | Phase I Schedule A. Volasertib 150 mg+LDAC | Phase I Schedule A. Volasertib 200 mg+LDAC | Phase I Schedule A. Volasertib 250 mg+LDAC | Phase I Schedule A. Volasertib 300 mg+LDAC | Phase I Schedule A. Volasertib 350 mg+LDAC | Phase I Schedule A. Volasertib 400 mg+LDAC | Total Phase I Combined. Schedule A. | Phase I Schedule B. Volasertib 150 mg | Phase I Schedule B. Volasertib 200 mg | Phase I Schedule B. Volasertib 350 mg | Phase I Schedule B. Volasertib 400 mg | Phase I Schedule B. Volasertib 450 mg | Phase I Schedule B. Volasertib 500 mg | Phase I Schedule B. Volasertib 550 mg | Total Phase I Combined. Schedule B. | Phase II Schedule C. LDAC | Phase II Schedule A. Volasertib 350 mg+LDAC | Total Phase II Combined. Schedule A and C. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Complete remission | 0 | 0 | 2 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 6 | 9 |
| CRi | 0 | 2 | 0 | 1 | 1 | 0 | 4 | 0 | 0 | 1 | 2 | 2 | 0 | 0 | 5 | 3 | 7 | 10 |
| Partial remission | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 1 | 4 | 2 | 2 | 4 |
| No change | 2 | 1 | 2 | 1 | 1 | 1 | 8 | 4 | 0 | 2 | 2 | 7 | 3 | 0 | 18 | 18 | 15 | 33 |
| Aplasia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 1 | 1 | 6 | 0 | 0 | 0 |
| Indeterminate | 0 | 0 | 0 | 2 | 3 | 1 | 6 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 5 | 8 |
| Progressive disease | 2 | 0 | 1 | 3 | 3 | 1 | 10 | 6 | 2 | 1 | 1 | 7 | 1 | 1 | 19 | 14 | 7 | 21 |
| Not evaluable | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 3 | 2 | 0 | 2 |
| Missing | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Phase I: Number of patients with Objective Response (Complete remission (CR) + Complete remission with incomplete blood count recovery (CRi)). Complete remission (CR): morphologically leukaemia-free state (i.e. bone marrow with \<5% blasts by morphologic criteria and no Auer rods, no evidence of extramedullary leukaemia) and absolute neutrophil count ≥1,000/microliter (μL) and platelets \>100,000/μL. Complete remission with incomplete blood count recovery ("incomplete" CR, CRi): all of the above criteria for CR were met except that neutrophils \<1,000/μL or platelets \<100,000/μL in the blood were not achieved.
| Participants | Phase I Schedule A. Volasertib 150 mg+LDAC | Phase I Schedule A. Volasertib 200 mg+LDAC | Phase I Schedule A. Volasertib 250 mg+LDAC | Phase I Schedule A. Volasertib 300 mg+LDAC | Phase I Schedule A. Volasertib 350 mg+LDAC | Phase I Schedule A. Volasertib 400 mg+LDAC | Total Phase I Combined. Schedule A. | Phase I Schedule B. Volasertib 150 mg | Phase I Schedule B. Volasertib 200 mg | Phase I Schedule B. Volasertib 350 mg | Phase I Schedule B. Volasertib 400 mg | Phase I Schedule B. Volasertib 450 mg | Phase I Schedule B. Volasertib 500 mg | Phase I Schedule B. Volasertib 550 mg | Total Phase I Combined. Schedule B. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phase I: Number of Patients With Objective Response: Complete Remission or Complete Remission With Incomplete Blood Count Recovery (CR+CRi) | 0 | 2 | 2 | 1 | 1 | 0 | 6 | 0 | 0 | 1 | 2 | 2 | 0 | 0 | 5 |
Event-free survival (EFS) \[days\] was the shortest duration of the following: (a) Date of assessment indicating PD on the response page of the eCRF (Electronic Case Report Form) - date of randomisation + 1 day (b) Date of assessment indicating clinical progressive disease (PD) on the disease or responses pages of the of eCRF- date of randomisation + 1 day (c) Date of assessment indicating PD on the patient status page of the eCRF - date of randomisation +1 day (for patients who had not been censored before this time point) (d) Death date - date of randomisation +1 day Patients not being assessed PD, clinical PD, or death during the trial were censored. EFS was analysed with the Kaplan-Meier method for each of the treatment arms.
| Days | Phase II Schedule C. LDAC | Phase II Schedule A. Volasertib 350 mg+LDAC |
|---|---|---|
| Phase II: Event Free Survival | 69.0 (27 to 215) | 169.0 (39 to 470) |
Overall survival \[days\] = (date of death - date of randomisation + 1 day), for patients with known date of death. Overall survival (censored) \[days\] = (date of last trial visit or follow-up - date of randomisation + 1 day), for patients who were still alive at time of database lock. Overall survival (OS) was analysed with the Kaplan-Meier method for each of the treatment arms.
| Days | Phase II Schedule C. LDAC | Phase II Schedule A. Volasertib 350 mg+LDAC |
|---|---|---|
| Phase II: Overall Survival | 158.0 (78 to 347) | 245.0 (73 to 689) |
Relapse-free survival \[days\] = (date of first recurrence of disease or death after entering the trial - date of first occurrence of CR or CRi after entering the trial+ 1 day) for patients with a recurrence (this value should be positive). Relapse-free survival (censored) \[days\] = (date of last trial visit or follow-up - date of first occurrence of CR or CRi after entering the trial + 1 day) for patients who did not experience recurrence of disease or death at the time of analysis.
| Days | Phase II Schedule C. LDAC | Phase II Schedule A. Volasertib 350 mg+LDAC |
|---|---|---|
| Phase II: Relapse - Free Survival | 304.0 (113 to 367) | 563.0 (427 to NA) |
Remission duration analysis was defined only for patients who achieved Complete remission (CR) or Complete remission with incomplete blood count recovery (CRi), and was measured from the date of attaining CR or CRi until the date of disease recurrence (relapse). For patients who died without report of relapse, remission duration was censored on the date of death, regardless of cause.
| Days | Phase II Schedule C. LDAC | Phase II Schedule A. Volasertib 350 mg+LDAC |
|---|---|---|
| Phase II: Remission Duration | 367.0 (113 to 367) | 687.0 (427 to NA) |
Time to remission \[days\] = (date of first occurrence of CR or CRi after entering the trial-date of randomisation + 1 day) for patients with an objective response.
| Days | Phase II Schedule C. LDAC | Phase II Schedule A. Volasertib 350 mg+LDAC |
|---|---|---|
| Phase II: Time to Remission | 63.5 (30 to 125) | 71.0 (29 to 158) |
ECOG performance score change from baseline to last visit of last cycle = ECOG performance score at last visit of the last cycle - ECOG performance score at baseline. ECOG performance score changes from baseline were also categorised on a 3-point categorical scale: deteriorated (-1), unchanged (0), and improved (1). The number of participants for category of ECOG score change is reported.
| Participants | Phase I Schedule A. Volasertib 150 mg+LDAC | Phase I Schedule A. Volasertib 200 mg+LDAC | Phase I Schedule A. Volasertib 250 mg+LDAC | Phase I Schedule A. Volasertib 300 mg+LDAC | Phase I Schedule A. Volasertib 350 mg+LDAC | Phase I Schedule A. Volasertib 400 mg+LDAC | Total Phase I Combined. Schedule A. | Phase I Schedule B. Volasertib 150 mg | Phase I Schedule B. Volasertib 200 mg | Phase I Schedule B. Volasertib 350 mg | Phase I Schedule B. Volasertib 400 mg | Phase I Schedule B. Volasertib 450 mg | Phase I Schedule B. Volasertib 500 mg | Phase I Schedule B. Volasertib 550 mg | Total Phase I Comined. Schedule B. | Phase II Schedule C. LDAC | Phase II Schedule A. Volasertib 350 mg+LDAC | Total Phase II. Schedule A and C. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Unchanged | 3 | 1 | 5 | 2 | 5 | 1 | 17 | 9 | 1 | 0 | 4 | 14 | 2 | 3 | 33 | 22 | 15 | 37 |
| Improved | 0 | 2 | 0 | 1 | 0 | 0 | 3 | 0 | 0 | 1 | 1 | 3 | 1 | 0 | 6 | 8 | 13 | 21 |
| Deteriorated | 1 | 0 | 0 | 2 | 3 | 1 | 7 | 1 | 1 | 4 | 1 | 5 | 2 | 0 | 14 | 12 | 11 | 23 |
Total Clearance (CL) of Volasertib in Plasma after Intravenous (i.v.) Administration of Volasertib.
| millilitre/minute (mL/min) | Phase I Schedule A. Volasertib 150 mg+LDAC | Phase I Schedule A. Volasertib 200 mg+LDAC | Phase I Schedule A. Volasertib 250 mg+LDAC | Phase I Schedule A. Volasertib 300 mg+LDAC | Phase I Schedule A. Volasertib 350 mg+LDAC | Phase I Schedule A. Volasertib 400 mg+LDAC | Phase I Schedule B. Volasertib 150 mg | Phase I Schedule B. Volasertib 200 mg | Phase I Schedule B. Volasertib 350 mg | Phase I Schedule B. Volasertib 400 mg | Phase I Schedule B. Volasertib 450 mg | Phase I Schedule B. Volasertib 500 mg | Phase I Schedule B. Volasertib 550 mg | Phase II Schedule A. Volasertib 350 mg+LDAC. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Clearance (CL) of Volasertib in Plasma After i.v (Intravenous) Administration of Volasertib | 1280 ± 52.8 | 972 ± 26.6 | 864 ± 27.6 | 1150 ± 34.4 | 1000 ± 36.2 | 852 ± 49.6 | 1330 ± 29.3 | NA ± NA | 810 ± 35.1 | 1120 ± 62.1 | 920 ± 36.2 | 1140 ± 38.5 | 939 ± 93.2 | 897 ± 42.8 |
Apparent Volume of Distribution of volasertib at steady state (VSS) following Intravenous (i.v.) administration.
| Liter (L) | Phase I Schedule A. Volasertib 150 mg+LDAC | Phase I Schedule A. Volasertib 200 mg+LDAC | Phase I Schedule A. Volasertib 250 mg+LDAC | Phase I Schedule A. Volasertib 300 mg+LDAC | Phase I Schedule A. Volasertib 350 mg+LDAC | Phase I Schedule A. Volasertib 400 mg+LDAC | Phase I Schedule B. Volasertib 150 mg | Phase I Schedule B. Volasertib 200 mg | Phase I Schedule B. Volasertib 350 mg | Phase I Schedule B. Volasertib 400 mg | Phase I Schedule B. Volasertib 450 mg | Phase I Schedule B. Volasertib 500 mg | Phase I Schedule B. Volasertib 550 mg | Phase II Schedule A. Volasertib 350 mg+LDAC. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apparent Volume of Distribution of Volasertib at Steady State (VSS) | 10600 ± 111.0 | 8640 ± 14.1 | 7000 ± 26.6 | 6320 ± 35.9 | 5270 ± 58.2 | 4830 ± 56.7 | 10300 ± 36.3 | NA ± NA | 5800 ± 35.1 | 7150 ± 70.6 | 5740 ± 38.7 | 6360 ± 50.1 | 5680 ± 81.9 | 6130 ± 42.0 |
Cmax, norm: Maximum measured concentration of Cytarabine in plasma. The dose normalisation was done by dividing by the dose applied. Unit: nanogram/milliliter/milligram: ((ng/mL)/mg). Dose groups of Phase I were combined by dose normalizing as pre specified in the study protocol.
| (ng/mL)/mg | Dose Normalized Volasertib+LDAC(Phase I,Schedule A). 150 to 400 mg Volasertib. | Dose Normalized Volasertib+LDAC (Schedule A). Phase II. 350 mg Volasertib. | Dose Normalized LDAC (Schedule C). Phase II. LDAC Monotherapy. |
|---|---|---|---|
| Dose Normalized Maximum Measured Concentration of Cytarabine in Plasma (Cmax, Norm) | 2.92 ± 61.3 | 2.83 ± 52.8 | 2.36 ± 77.6 |
AUC0-4,norm: Area under the concentration-time curve of Cytarabine in plasma over the time interval from zero extrapolated to 4 hours. The dose normalisation was done by dividing by dose applied. Unit: nanogram\*hour/milliliter/milligram: ((ng\*h/mL)/mg). Dose groups of Phase I were combined by dose normalizing as pre specified in the study protocol.
| (ng*h/mL)/mg | Dose Normalized Volasertib+LDAC(Phase I,Schedule A). 150 to 400 mg Volasertib. | Dose Normalized Volasertib+LDAC (Schedule A). Phase II. 350 mg Volasertib. | Dose Normalized LDAC (Schedule C). Phase II. LDAC Monotherapy. |
|---|---|---|---|
| Dose Normalized Area Under the Concentration-Time Curve of Cytarabine in Plasma Over the Time Interval From 0 Extrapolated up to 4 Hours | 3.84 ± 30.6 | 4.00 ± 35.6 | 3.94 ± 43.8 |
ECG (Electro Cardio Gram) Measurements: Absolute QTcF (QT Interval (interval from the beginning of the QRS complex to the end of the T wave) Corrected for Heart Rate Using Fridericia's Formula) Intervals. The 350 mg + LDAC arm of phase I and II were combined into one arm to provide maximum information on QT changes and presented together with the Phase I schedule B 450 mg arm, as pre specified in the study protocol.
| milliseconds (ms) | Phase I+II Volasertib 350 mg+LDAC | Phase I Schedule B. Volasertib 450 mg |
|---|---|---|
| Individual baseline | 411.6 ± 20.7 | 412.4 ± 18.7 |
| 1 hour after start of infusion | 430.0 ± 20.4 | 441.1 ± 20.0 |
| 24 hour after start of infusion | 414.0 ± 21.3 | 411.9 ± 18.4 |
ECG Measurements: QTcF (QT Interval (interval from the beginning of the QRS complex to the end of the T wave) changes from baseline at each time point: The QTcF post baseline measurement obtained at time t minus baseline QTcF measurement. The 350 mg + LDAC arm of phase I and II were combined into one arm to provide maximum information on QT changes and presented together with the Phase I schedule B 450 mg arm, as pre specified in the study protocol.
| millisecond (ms) | Phase I+II, Volasertib 350 mg+LDAC | Phase I Schedule B. Volasertib 450 mg |
|---|---|---|
| Change from baseline after 1 hour | 18.5 ± 10.4 | 29.6 ± 8.1 |
| Change from baseline after 24 hour | 1.9 ± 10.5 | -0.5 ± 9.8 |
Number of patients with AEs following in the categories 3 (severe AE), 4 (life-threatening or disabling AE), 5 (death related AE) of CTCAE is reported.
| Participants | Phase I Schedule A. Volasertib 150 mg+LDAC | Phase I Schedule A. Volasertib 200 mg+LDAC | Phase I Schedule A. Volasertib 250 mg+LDAC | Phase I Schedule A. Volasertib 300 mg+LDAC | Phase I Schedule A. Volasertib 350 mg+LDAC | Phase I Schedule A. Volasertib 400 mg+LDAC | Total Phase I Combined. Schedule A. |
|---|---|---|---|---|---|---|---|
| Grade 3 | 0 | 0 | 1 | 1 | 2 | 1 | 5 |
| Grade 4 | 2 | 3 | 3 | 5 | 3 | 1 | 17 |
| Grade 5 | 0 | 0 | 0 | 3 | 2 | 1 | 6 |
Number of patients with AEs following in the categories 3 (severe AE), 4 (life-threatening or disabling AE), 5 (death related AE) of CTCAE is reported.
| Participants | Phase I Schedule B. Volasertib 150 mg | Phase I Schedule B. Volasertib 200 mg | Phase I Schedule B. Volasertib 350 mg | Phase I Schedule B. Volasertib 400 mg | Phase I Schedule B. Volasertib 450 mg | Phase I Schedule B. Volasertib 500 mg | Phase I Schedule B. Volasertib 550 mg | Total Phase I Schedule B. |
|---|---|---|---|---|---|---|---|---|
| Grade 3 | 5 | 0 | 1 | 0 | 5 | 0 | 0 | 11 |
| Grade 4 | 4 | 1 | 3 | 4 | 14 | 1 | 3 | 30 |
| Grade 5 | 1 | 1 | 0 | 0 | 2 | 1 | 1 | 6 |
Number of patients with AEs following in the categories 3 (severe AE), 4 (life-threatening or disabling AE), 5 (death related AE) of CTCAE is reported.
| Participants | Phase I Schedule A. Volasertib 150 mg+LDAC | Phase I Schedule A. Volasertib 200 mg+LDAC | Phase I Schedule A. Volasertib 250 mg+LDAC | Phase I Schedule A. Volasertib 300 mg+LDAC | Phase I Schedule A. Volasertib 350 mg+LDAC | Phase I Schedule A. Volasertib 400 mg+LDAC | Total Phase I Combined. Schedule A. |
|---|---|---|---|---|---|---|---|
| Grade 3 | 1 | 0 | 0 | 1 | 2 | 1 | 5 |
| Grade 4 | 1 | 3 | 5 | 5 | 3 | 1 | 18 |
| Grade 5 | 1 | 0 | 0 | 3 | 2 | 1 | 7 |
Number of patients with AEs following in the categories 3 (severe AE), 4 (life-threatening or disabling AE), 5 (death related AE) of CTCAE is reported.
| Participants | Phase I Schedule B. Volasertib 150 mg | Phase I Schedule B. Volasertib 200 mg | Phase I Schedule B. Volasertib 350 mg | Phase I Schedule B. Volasertib 400 mg | Phase I Schedule B. Volasertib 450 mg | Phase I Schedule B. Volasertib 500 mg | Phase I Schedule B. Volasertib 550 mg | Total Phase I Schedule B. |
|---|---|---|---|---|---|---|---|---|
| Grade 3 | 5 | 0 | 1 | 0 | 3 | 0 | 0 | 9 |
| Grade 4 | 4 | 1 | 3 | 5 | 15 | 1 | 3 | 32 |
| Grade 5 | 2 | 1 | 0 | 0 | 3 | 2 | 1 | 9 |
Number of patients with AEs following in the in the categories 3 (severe AE), 4 (life-threatening or disabling AE), 5 (death related AE) of CTCAE is reported.
| Participants | Phase II Schedule C. LDAC | Phase II Schedule A. Volasertib 350 mg+LDAC |
|---|---|---|
| Grade 3 | 13 | 12 |
| Grade 4 | 13 | 20 |
| Grade 5 | 6 | 8 |
Collected over From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase II Schedule C. LDAC | 45/45 (100%) | 29/45 (64.4%) | 43/45 (95.6%) |
| Phase I Schedule A. Volasertib 150 mg+LDAC | 4/4 (100%) | 2/4 (50%) | 4/4 (100%) |
| Phase I Schedule A. Volasertib 200 mg+LDAC | 3/3 (100%) | 3/3 (100%) | 3/3 (100%) |
| Phase I Schedule A. Volasertib 250 mg+LDAC | 4/5 (80%) | 3/5 (60%) | 5/5 (100%) |
| Phase I Schedule A. Volasertib 300 mg+LDAC | 9/9 (100%) | 7/9 (77.8%) | 9/9 (100%) |
| Phase I Schedule A. Volasertib 350 mg+LDAC | 8/8 (100%) | 6/8 (75%) | 8/8 (100%) |
| Phase II Schedule A. Volasertib 350 mg+LDAC | 38/42 (90.5%) | 34/42 (81%) | 41/42 (97.6%) |
| Phase I Schedule A. Volasertib 400 mg+LDAC | 3/3 (100%) | 3/3 (100%) | 3/3 (100%) |
| Phase I Schedule B. Volasertib 150 mg | 11/11 (100%) | 7/11 (63.6%) | 11/11 (100%) |
| Phase I Schedule B. Volasertib 200 mg | 2/2 (100%) | 1/2 (50%) | 2/2 (100%) |
| Phase I Schedule B. Volasertib 350 mg | 3/5 (60%) | 3/5 (60%) | 5/5 (100%) |
| Phase I Schedule B. Volasertib 400 mg | 6/6 (100%) | 3/6 (50%) | 6/6 (100%) |
| Phase I Schedule B. Volasertib 450 mg | 21/23 (91.3%) | 16/23 (69.6%) | 23/23 (100%) |
| Phase I Schedule B. Volasertib 500 mg | 5/5 (100%) | 3/5 (60%) | 5/5 (100%) |
| Phase I Schedule B. Volasertib 550 mg | 4/4 (100%) | 3/4 (75%) | 4/4 (100%) |
| Event | Phase II Schedule C. LDAC | Phase I Schedule A. Volasertib 150 mg+LDAC | Phase I Schedule A. Volasertib 200 mg+LDAC | Phase I Schedule A. Volasertib 250 mg+LDAC | Phase I Schedule A. Volasertib 300 mg+LDAC | Phase I Schedule A. Volasertib 350 mg+LDAC | Phase II Schedule A. Volasertib 350 mg+LDAC | Phase I Schedule A. Volasertib 400 mg+LDAC | Phase I Schedule B. Volasertib 150 mg | Phase I Schedule B. Volasertib 200 mg | Phase I Schedule B. Volasertib 350 mg | Phase I Schedule B. Volasertib 400 mg | Phase I Schedule B. Volasertib 450 mg | Phase I Schedule B. Volasertib 500 mg | Phase I Schedule B. Volasertib 550 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 6/45 | 2/4 | 2/3 | 2/5 | 2/9 | 3/8 | 23/42 | 2/3 | 0/11 | 0/2 | 0/5 | 2/6 | 9/23 | 2/5 | 1/4 |
| C-reactive protein increasedInvestigations | 0/45 | 0/4 | 0/3 | 3/5 | 1/9 | 0/8 | 0/42 | 0/3 | 1/11 | 0/2 | 1/5 | 0/6 | 0/23 | 0/5 | 0/4 |
| DiarrhoeaGastrointestinal disorders | 1/45 | 0/4 | 0/3 | 1/5 | 0/9 | 0/8 | 2/42 | 0/3 | 0/11 | 1/2 | 0/5 | 0/6 | 0/23 | 0/5 | 0/4 |
| Mucosal inflammationGeneral disorders | 1/45 | 0/4 | 0/3 | 0/5 | 0/9 | 0/8 | 0/42 | 1/3 | 1/11 | 0/2 | 0/5 | 1/6 | 1/23 | 0/5 | 2/4 |
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/45 | 0/4 | 0/3 | 0/5 | 1/9 | 0/8 | 2/42 | 0/3 | 1/11 | 1/2 | 0/5 | 0/6 | 0/23 | 0/5 | 0/4 |
| PneumoniaInfections and infestations | 2/45 | 0/4 | 0/3 | 0/5 | 1/9 | 0/8 | 8/42 | 0/3 | 3/11 | 0/2 | 0/5 | 0/6 | 4/23 | 2/5 | 1/4 |
| ArrhythmiaCardiac disorders | 0/45 | 0/4 | 1/3 | 0/5 | 0/9 | 0/8 | 0/42 | 0/3 | 0/11 | 0/2 | 0/5 | 0/6 | 0/23 | 0/5 | 0/4 |
| Myocardial ischaemiaCardiac disorders | 0/45 | 0/4 | 1/3 | 0/5 | 0/9 | 0/8 | 0/42 | 0/3 | 0/11 | 0/2 | 0/5 | 0/6 | 0/23 | 0/5 | 0/4 |
| General physical health deteriorationGeneral disorders | 5/45 | 0/4 | 1/3 | 1/5 | 2/9 | 1/8 | 1/42 | 1/3 | 1/11 | 0/2 | 0/5 | 0/6 | 1/23 | 0/5 | 0/4 |
| PainGeneral disorders | 0/45 | 0/4 | 1/3 | 0/5 | 0/9 | 0/8 | 0/42 | 0/3 | 0/11 | 0/2 | 0/5 | 0/6 | 0/23 | 0/5 | 0/4 |
| Event | Phase II Schedule C. LDAC | Phase I Schedule A. Volasertib 150 mg+LDAC | Phase I Schedule A. Volasertib 200 mg+LDAC | Phase I Schedule A. Volasertib 250 mg+LDAC | Phase I Schedule A. Volasertib 300 mg+LDAC | Phase I Schedule A. Volasertib 350 mg+LDAC | Phase II Schedule A. Volasertib 350 mg+LDAC | Phase I Schedule A. Volasertib 400 mg+LDAC | Phase I Schedule B. Volasertib 150 mg | Phase I Schedule B. Volasertib 200 mg | Phase I Schedule B. Volasertib 350 mg | Phase I Schedule B. Volasertib 400 mg | Phase I Schedule B. Volasertib 450 mg | Phase I Schedule B. Volasertib 500 mg | Phase I Schedule B. Volasertib 550 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 12/45 | 1/4 | 2/3 | 4/5 | 6/9 | 3/8 | 14/42 | 1/3 | 4/11 | 2/2 | 5/5 | 4/6 | 11/23 | 1/5 | 2/4 |
| ConstipationGastrointestinal disorders | 12/45 | 0/4 | 3/3 | 2/5 | 2/9 | 3/8 | 18/42 | 0/3 | 3/11 | 1/2 | 0/5 | 1/6 | 6/23 | 1/5 | 2/4 |
| FatigueGeneral disorders | 11/45 | 1/4 | 1/3 | 5/5 | 5/9 | 4/8 | 11/42 | 1/3 | 3/11 | 2/2 | 1/5 | 0/6 | 4/23 | 2/5 | 2/4 |
| Alanine aminotransferase increasedInvestigations | 1/45 | 0/4 | 3/3 | 1/5 | 0/9 | 0/8 | 0/42 | 0/3 | 2/11 | 0/2 | 0/5 | 1/6 | 4/23 | 1/5 | 0/4 |
| C-reactive protein increasedInvestigations | 5/45 | 2/4 | 1/3 | 2/5 | 4/9 | 4/8 | 2/42 | 1/3 | 4/11 | 2/2 | 1/5 | 3/6 | 7/23 | 1/5 | 3/4 |
| HyperglycaemiaMetabolism and nutrition disorders | 2/45 | 1/4 | 2/3 | 4/5 | 1/9 | 0/8 | 0/42 | 0/3 | 1/11 | 2/2 | 0/5 | 0/6 | 1/23 | 0/5 | 0/4 |
| HypocalcaemiaMetabolism and nutrition disorders | 1/45 | 0/4 | 1/3 | 3/5 | 2/9 | 1/8 | 2/42 | 0/3 | 2/11 | 2/2 | 2/5 | 1/6 | 6/23 | 1/5 | 0/4 |
| HypokalaemiaMetabolism and nutrition disorders | 3/45 | 0/4 | 1/3 | 4/5 | 4/9 | 6/8 | 8/42 | 3/3 | 2/11 | 0/2 | 0/5 | 0/6 | 10/23 | 0/5 | 2/4 |
| Blood blisterSkin and subcutaneous tissue disorders | 0/45 | 0/4 | 0/3 | 0/5 | 0/9 | 1/8 | 1/42 | 0/3 | 1/11 | 2/2 | 0/5 | 1/6 | 0/23 | 0/5 | 0/4 |
| ThrombocytopeniaBlood and lymphatic system disorders | 8/45 | 0/4 | 2/3 | 4/5 | 5/9 | 3/8 | 9/42 | 1/3 | 5/11 | 1/2 | 3/5 | 2/6 | 12/23 | 1/5 | 2/4 |
Treated Set: All patients in Phase I who received at least a single dose of either Volasertib or LDAC, including patients who were replaced for any reason. For the Phase II part, the treated set (Phase II) was defined as all patients in Phase II who received at least a single dose of either Volasertib or LDAC.
| Age, Continuous(Years) | Phase I Schedule A. Volasertib 150 mg+LDAC | Phase I Schedule A. Volasertib 200 mg+LDAC | Phase I Schedule A. Volasertib 250 mg+LDAC | Phase I Schedule A. Volasertib 300 mg+LDAC | Phase I Schedule A. Volasertib 350 mg+LDAC | Phase I Schedule A. Volasertib 400 mg+LDAC | Phase I Schedule B. Volasertib 150 mg | Phase I Schedule B. Volasertib 200 mg | Phase I Schedule B. Volasertib 350 mg | Phase I Schedule B. Volasertib 400 mg | Phase I Schedule B. Volasertib 450 mg | Phase I Schedule B. Volasertib 500 mg | Phase I Schedule B. Volasertib 550 mg | Phase II Schedule C. LDAC | Phase II Schedule A. Volasertib 350 mg+LDAC | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 69.5 ± 12.1 | 67.0 ± 3.0 | 71.2 ± 6.8 | 67.9 ± 12.0 | 72.5 ± 6.1 | 73.3 ± 7.6 | 73.5 ± 3.9 | 73.0 ± 4.2 | 70.6 ± 2.9 | 65.2 ± 20.1 | 68.2 ± 7.7 | 66.4 ± 7.3 | 69.8 ± 4.1 | 75.2 ± 5.5 | 75.6 ± 4.9 | 72.5 ± 7.7 |
| Sex: Female, Male(Participants) | Phase I Schedule A. Volasertib 150 mg+LDAC | Phase I Schedule A. Volasertib 200 mg+LDAC | Phase I Schedule A. Volasertib 250 mg+LDAC | Phase I Schedule A. Volasertib 300 mg+LDAC | Phase I Schedule A. Volasertib 350 mg+LDAC | Phase I Schedule A. Volasertib 400 mg+LDAC | Phase I Schedule B. Volasertib 150 mg | Phase I Schedule B. Volasertib 200 mg | Phase I Schedule B. Volasertib 350 mg | Phase I Schedule B. Volasertib 400 mg | Phase I Schedule B. Volasertib 450 mg | Phase I Schedule B. Volasertib 500 mg | Phase I Schedule B. Volasertib 550 mg | Phase II Schedule C. LDAC | Phase II Schedule A. Volasertib 350 mg+LDAC | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 2 | 0 | 2 | 3 | 3 | 1 | 3 | 1 | 3 | 2 | 16 | 1 | 3 | 20 | 19 | 79 |
| Male | 2 | 3 | 3 | 6 | 5 | 2 | 8 | 1 | 2 | 4 | 7 | 4 | 1 | 25 | 23 | 96 |
| Race (NIH/OMB)(Participants) | Phase I Schedule A. Volasertib 150 mg+LDAC | Phase I Schedule A. Volasertib 200 mg+LDAC | Phase I Schedule A. Volasertib 250 mg+LDAC | Phase I Schedule A. Volasertib 300 mg+LDAC | Phase I Schedule A. Volasertib 350 mg+LDAC | Phase I Schedule A. Volasertib 400 mg+LDAC | Phase I Schedule B. Volasertib 150 mg | Phase I Schedule B. Volasertib 200 mg | Phase I Schedule B. Volasertib 350 mg | Phase I Schedule B. Volasertib 400 mg | Phase I Schedule B. Volasertib 450 mg | Phase I Schedule B. Volasertib 500 mg | Phase I Schedule B. Volasertib 550 mg | Phase II Schedule C. LDAC | Phase II Schedule A. Volasertib 350 mg+LDAC | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Asian | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 4 | 3 | 4 | 8 | 8 | 3 | 11 | 2 | 5 | 6 | 21 | 5 | 4 | 35 | 34 | 153 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 8 | 7 | 17 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2008 to primary completion in Mar 2012, 39 months.
Results were first posted in Oct 2023, 11 years 6 months after primary completion.
Of 57 industry-sponsored phase 2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 55. This study's 39 months is close to that.
Counting every sponsor, half of 443 studies reached it within 60 months; a quarter within 38 and three quarters within 104.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: BI 6727 · Cytarabine